Skip to content
B
BiotechEdge

Weekly Brief

Week of March 9, 2026

Top smart money signals, catalyst updates, and insider activity.

Share

What happened in biotech the week of March 9, 2026?

This week in biotech: 15 fund position changes across 15 companies. 10 catalyst outcomes including ARWR. 5 high-conviction convergence signals. 1 catalyst expected in the next two weeks.

Smart Money MovesQ1 2026· 15 moves

PRAX5 funds increased

Perceptive Advisors, Baker Bros. Advisors, Deerfield Management, Driehaus Capital, Cormorant Asset Management

CELC4 funds increased

Baker Bros. Advisors, Avoro Capital Advisors, Perceptive Advisors, RTW Investments

RVMD4 funds increased

Baker Bros. Advisors, BVF Partners, Avoro Capital Advisors, Deerfield Management

INSM2 funds increased

Baker Bros. Advisors, RTW Investments

UTHR2 funds held

Avoro Capital Advisors, Deerfield Management

ASND2 funds trimmed

Avoro Capital Advisors, Perceptive Advisors

ARGX2 funds increased

Avoro Capital Advisors, RTW Investments

PCVX2 funds increased

RA Capital Management, Deep Track Capital

Dollar amounts and AI context available with a free trial.

Catalyst Outcomes This Week

ARWRNegativePhase 2 Readout
ARC-520 Injection
NKTRNegativePhase 3 Readout
NKTR-255 at 1.5 µg/kg
ICLRPositivePhase 3 Readout
IBI-10090
ARWRPositivePhase 2 Readout
ARO-APOC3
SNSENegativePhase 2 Readout
SNS-301
VRTXPositivePhase 3 Readout
ELX/TEZ/IVA
ALNYNegativePhase 2 Readout
ALN-RSV01
NKTRPositivePhase 2 Readout
Bempegaldesleukin
AZNPositivePhase 3 Readout
OMERNegativePhase 2 Readout
OMS643762

Catalysts Ahead

15 catalysts in the next 30 days

UTHRPhase 2 ReadoutrF1V-1018
May 29, 2026
PFEPhase 2 ReadoutMultivalent Pneumococcal Vaccine - Formulation 1
Q2 2026
AZNPhase 2 ReadoutAZD9550
Q2 2026
AZNPhase 2 ReadoutAZD6234
Q2 2026
AMGNPhase 2 ReadoutAnvumetostat
Q2 2026
AZNPhase 3 ReadoutDurvalumab
Q2 2026
VRTXPhase 2 ReadoutVX-264
Q2 2026
DVAXPhase 2 ReadoutrF1V-1018
Q2 2026
AMGNPhase 2 Readoutsotorasib
Q2 2026
ABBVPhase 2 ReadoutTNB-383B
Q2 2026
TNGXPhase 2 ReadoutTNG462
Q2 2026
SGENPhase 2 Readoutdisitamab vedotin
Q2 2026
ALTPhase 2 ReadoutPemvidutide
Q2 2026
ABBVPhase 3 ReadoutPlacebo for Risankizumab SC
Q2 2026
GHPhase 2 ReadoutOsimertinib
Q2 2026

High Conviction — Fund Convergence

GPCR10 fundsStructure Therapeutics Inc.
KYMR9 fundsKymera Therapeutics Inc.
CMPS9 fundsCOMPASS Pathways plc
RVMD8 fundsRevolution Medicines Inc.
CNTA8 fundsCentessa Pharmaceuticals plc

Research This Week

Short Interest — Notable Changes

CNTASI Falling
-- %
ALTSI Rising
-- %
RVMDSI Falling
-- %
XENESI Falling
-- %
UTHRSI Falling
-- %
AZNSI Rising
-- %
CGONSI Falling
-- %
AMGNSI Falling
-- %

Exact short interest %, share counts, and days to cover with a free trial.

Get this in your inbox every Monday

Plus dollar amounts, AI analyst context, watchlist alerts, and full dashboard access.

Start 14-Day Free Trial — $29/mo

Share this brief